Stock SUPN SUPERNUS PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Supernus Pharmaceuticals, Inc.

Equities

SUPN

US8684591089

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
30.07 USD +2.59% Intraday chart for Supernus Pharmaceuticals, Inc. +2.28% +3.90%
Apr. 08 Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready DJ
Apr. 08 Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket MT

Evolution of the average Target Price on Supernus Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

e2cd3.BAhrRs1jprYUptcKJRbcOqMMp6Z_bpSjtjMN9uEZ9Qo.MW09P6pSydNO5aQ8RF2ectIhwM45Wd-bgkR3wbNcs0JSTjkEphTEgTn2uA~36b7af8494ce6c12d996a027c4c4e6fc

Analyst Recommendations on Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing MT
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating MT
Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $46 From $45, Keeps Overweight Rating MT
Piper Sandler Adjusts Supernus Pharmaceuticals Price Target to $47 From $40, Maintains Overweight Rating MT
Piper Sandler Adjusts Price Target on Supernus Pharmaceuticals to $38 From $33, Reiterates Overweight Rating MT
Jefferies Reinstates Supernus Pharmaceuticals at Buy With $44 Price Target MT
SUPERNUS PHARMACEUTICALS : Jefferies Lifts Supernus Pharmaceuticals to Buy From Hold, Price Target to $40 From $25 MT
SUPERNUS PHARMACEUTICALS : Piper Sandler Adjusts Supernus Pharmaceuticals PT to $35 From $30, Maintains Overweight Rating MT
Supernus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018; Revises Earnings Guidance for the Full Year of 2018; Provides Tax Rate Guidance for the Fourth Quarter of 2018 CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
30.07 USD
Average target price
40.33 USD
Spread / Average Target
+34.13%
High Price Target
43 USD
Spread / Highest target
+43.00%
Low Price Target
38 USD
Spread / Lowest Target
+26.37%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Supernus Pharmaceuticals, Inc.

Piper Sandler
Jefferies & Co.

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. SUPN Stock
  4. Consensus Supernus Pharmaceuticals, Inc.